Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHYOX3: Long-Term Safety and Efficacy of Nedosiran in Primary Hyperoxaluria
NCT04042402Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2019
- Primary completion
- Apr 2030
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 13
01
Overview
A Phase 3 trial of nedosiran in Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), primary hyperoxaluria type 3 (PH3), sponsored by Novo Nordisk. Started Jul 2019; status: active, not recruiting.
02
Drugs
nedosiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 2 (PH2)primary hyperoxaluria type 3 (PH3)
Beyond the preview
Go deeper on NCT04042402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042402.